150 related articles for article (PubMed ID: 29294465)
1. Triptorelin (Triptodur) for central precocious puberty.
Med Lett Drugs Ther; 2018 Jan; 60(1537):7-8. PubMed ID: 29294465
[No Abstract] [Full Text] [Related]
2. Six-year results of luteinizing hormone releasing hormone (LHRH) agonist treatment in children with LHRH-dependent precocious puberty.
Manasco PK; Pescovitz OH; Hill SC; Jones JM; Barnes KM; Hench KD; Loriaux DL; Cutler GB
J Pediatr; 1989 Jul; 115(1):105-8. PubMed ID: 2661787
[No Abstract] [Full Text] [Related]
3. Triptorelin depot for the treatment of children 2 years and older with central precocious puberty.
Bertelloni S; Mucaria C; Baroncelli GI; Peroni D
Expert Rev Clin Pharmacol; 2018 Jul; 11(7):659-667. PubMed ID: 29957076
[TBL] [Abstract][Full Text] [Related]
4. [D-Trp-6 gonadotropin analog releasing hormone (Decapeptyl-Depot)-- the drug of choice in central idiopathic precocious puberty].
Hníková O; Janecková M; Finková M
Cesk Pediatr; 1994; 49(1):22-4. PubMed ID: 8124745
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.
Klein K; Yang J; Aisenberg J; Wright N; Kaplowitz P; Lahlou N; Linares J; Lundström E; Purcea D; Cassorla F
J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1241-1248. PubMed ID: 26887034
[TBL] [Abstract][Full Text] [Related]
6. [Undulating course of precocious puberty].
Kolmer M; Schulz U; Herkner K; Frisch H; Waldhauser F
Padiatr Padol; 1991; 26(6):271-4. PubMed ID: 1838804
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
Liang Y; Wei H; Zhang JL; Hou L; Luo XP
Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
[TBL] [Abstract][Full Text] [Related]
8. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology.
Heinrichs C; Craen M; Vanderschueren-Lodeweyckx M; Malvaux P; Fawe L; Bourguignon JP
Acta Paediatr; 1994 Jun; 83(6):627-33. PubMed ID: 7919761
[TBL] [Abstract][Full Text] [Related]
9. Hair loss in children on long-acting gonadotropin-releasing hormone agonist triptorelin treatment.
Kauschansky A; Lurie R; Ingber A
Acta Derm Venereol; 1997 Jul; 77(4):333. PubMed ID: 9228240
[No Abstract] [Full Text] [Related]
10. [Long-term experiences with a long-acting gonadotropin releasing hormone analog in therapy of central precocious puberty: effect on body growth].
Hofmann-Ehrhart B; Schulz U; Kluge M; Wandl-Vergesslich K; Waldhauser F
Wien Klin Wochenschr; 1995; 107(14):413-7. PubMed ID: 7668000
[TBL] [Abstract][Full Text] [Related]
11. Does the risk of arterial hypertension increase in the course of triptorelin treatment?
Palma L; Gaudino R; Cavarzere P; Antoniazzi F
J Pediatr Endocrinol Metab; 2020 Mar; 33(3):449-452. PubMed ID: 30091950
[TBL] [Abstract][Full Text] [Related]
12. Central precocious puberty due to hypothalamic hamartoma in a 7-month-old infant girl.
Rousso IH; Kourti M; Papandreou D; Tragiannidis A; Athanasiadou F
Eur J Pediatr; 2008 May; 167(5):583-5. PubMed ID: 17541635
[TBL] [Abstract][Full Text] [Related]
13. Effects of luteinizing hormone-releasing hormone agonists on final height in luteinizing hormone-releasing hormone-dependent precocious puberty.
Oerter KE; Manasco PK; Barnes KM; Jones J; Hill S; Cutler GB
Acta Paediatr Suppl; 1993 Mar; 388():62-8; discussion 69. PubMed ID: 8329833
[No Abstract] [Full Text] [Related]
14. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation.
Martínez-Aguayo A; Hernández MI; Beas F; Iñiguez G; Avila A; Sovino H; Bravo E; Cassorla F
J Pediatr Endocrinol Metab; 2006 Aug; 19(8):963-70. PubMed ID: 16995580
[TBL] [Abstract][Full Text] [Related]
15. A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate.
Zenaty D; Blumberg J; Liyanage N; Jacqz-Aigrain E; Lahlou N; Carel JC;
Horm Res Paediatr; 2016; 86(3):188-195. PubMed ID: 27603324
[TBL] [Abstract][Full Text] [Related]
16. Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation
.
Durand A; Tauber M; Patel B; Dutailly P
Horm Res Paediatr; 2017; 87(4):224-232. PubMed ID: 28334719
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of central precocious puberty with sustained-release triptorelin].
Boucekkine C; Blumberg-Tick J; Roger M; Thomas F; Chaussain JL
Arch Pediatr; 1994 Dec; 1(12):1127-37. PubMed ID: 7849900
[TBL] [Abstract][Full Text] [Related]
18. Time to menarche and final height after histrelin implant treatment for central precocious puberty.
Gillis D; Karavani G; Hirsch HJ; Strich D
J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026
[TBL] [Abstract][Full Text] [Related]
19. Pseudotumour Cerebri Presentation in a Child Under the Gonadotropin-Releasing Hormone Agonist Treatment.
Gül Ü; Kaçar Bayram A; Kendirci M; Hatipoğlu N; Okdemir D; Gümüş H; Kurtoğlu S
J Clin Res Pediatr Endocrinol; 2016 Sep; 8(3):365-7. PubMed ID: 27087351
[TBL] [Abstract][Full Text] [Related]
20. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
Carel JC; Blumberg J; Seymour C; Adamsbaum C; Lahlou N;
Eur J Endocrinol; 2006 Jan; 154(1):119-24. PubMed ID: 16382000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
